Media ReleasesNoxopharm

View All Noxopharm News


Noxopharm Announces Combination of Veyonda plus Radiotherapy Delivers Clinical Benefits

- Interim (12-week) DARRT-1 readout

- Combination Veyonda + low-dose radiotherapy well tolerated

- PSA, pain and tumour responses at higher doses

- 24-week readout to indicate longevity of response.

SYDNEY, February 6, 2019: Noxopharm (ASX:NOX) announces interim (12-week) results from the dose-ranging component of the DARRT-1 study.


For further information please download PDF attached:
Download this document